News

News

FDA Approves First Biosimilar Drug, New Indication for Lenalidomide, and more

FDA Approves First Biosimilar Drug Zarxio (filgrastim-sndz), a biosimilar product of filgrastim, was recently approved by the U.S. Food and Drug Administration (FDA). This is...

ACE-536 for MDS, Vorinostat in SCD, and more

LEUKEMIA Selected by David Steensma, MD A Phase 2, Open-Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1...

Do Clinical Trials Underreport Cancer Drug Toxicities?

Clinical trials may be underreporting patient toxicities from cancer drugs – by up to 75 percent in some cases – according to a new...
WIB_icon

Rituximab Plus Recombinant Human Thrombopoietin: Fast Results in Immune Thrombocytopenia

Although corticosteroids or intravenous immunoglobulin are typical first- and second-line treatments for immune thrombocytopenia (ITP), about one-third of patients do not respond to these...
WIB_icon

MDS/MPN Overlap: The Time is Now for Uniform Response Criteria

Myelodysplastic syndromes (MDS)/myeloproliferative neoplasms (MPNs) are clonal myeloid disorders possessing both dysplastic and proliferative features that cannot be classified as one or the other...

Order of Gene Mutation: Predicting What Cancer Will Do Next

Over the last decade, scientists have gained a much greater understanding of which genes acquire mutations in particular cancers. Now, new research is showing...

Can Genetic Sequencing Provide Insights into Disease and Hematopoiesis?

Sequencing of genomic data is increasingly becoming a valuable tool in identifying disease etiology in diagnostically challenging cases, as one research team discovered while...
WIB_icon

A Surprising Conclusion: High-Cost Blood Cancer Treatments May Be Cost-Effective

Although the past 15 years have seen great progress in the treatment of hematologic malignancies, these innovative therapies have left payers and patients with...
WIB_icon

Low-Molecular-Weight Heparin Fails to Boost Live Birth Rates in Women with Recurrent Miscarriage

Antithrombotic medications are often prescribed to women with histories of unexplained recurrent miscarriages, although there is little evidence of the efficacy of this approach....

LRF Awards Grants, NCI Awards UT Southwestern Funding, and more

LRF Awards Grants to Study Lymphoma in Adolescent, Young Adult Patients As part of a partnership with The Paul Foundation on Critical Adolescent and Young...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.